CDH1 and neoplasm: Q702 treatment induced antitumor activity and improved the efficacy of anti-PD-1 therapy by reducing the number of M2 macrophages and MDSCs, inducing M1 macrophages and cytotoxic CD8 T cells, and increasing the expression of MHC-I and E-cadherin in tumor cells in the TME.